← Back to Search

Monoclonal Antibodies

INBRX-109 for Chondrosarcoma (ChonDRAgon Trial)

Phase 2
Recruiting
Research Sponsored by Inhibrx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Conventional chondrosarcoma, unresectable (=inoperable) or metastatic
Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously irradiated (or other locally treated) area will be considered measurable, provided there has been clear imaging-based progression of the lesions since the time of treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

ChonDRAgon Trial Summary

This trial is testing a new drug to treat a type of bone cancer.

Who is the study for?
This trial is for people with a type of bone cancer called conventional chondrosarcoma that can't be removed by surgery or has spread. Participants must have shown disease progression recently, be in fairly good health (ECOG PS 0 or 1), and have a life expectancy of at least 12 weeks. They cannot join if they've had certain immune disorders like MS, allergies to the study drug or similar drugs made from Chinese hamster ovary cells, or previous treatment with DR5 agonists.Check my eligibility
What is being tested?
The study is testing INBRX-109 against a placebo in patients with advanced chondrosarcoma. It's a Phase 2 trial where participants are randomly assigned to receive either the real drug or a fake one without knowing which one they're getting. The goal is to see if INBRX-109 helps control the cancer better than no active treatment.See study design
What are the potential side effects?
Possible side effects of INBRX-109 may include reactions related to the immune system since it's an antibody-based therapy. Specific side effects aren't listed but could resemble those typical of other antibodies such as infusion reactions, fatigue, allergic responses, and increased risk of infections.

ChonDRAgon Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My chondrosarcoma cannot be removed by surgery or has spread.
Select...
My cancer can be measured by scans and has grown since any local treatments like radiation.
Select...
My cancer has worsened in the last 6 months according to scans.
Select...
I am fully active or can carry out light work.
Select...
You are expected to live for at least 12 more weeks.

ChonDRAgon Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival per RECISTv1.1 comparing INBRX-109 and placebo
Secondary outcome measures
Characterize the pharmacokinetics of INBRX-109.
DCR per RECISTv1.1 by real-time IRR
DOR per RECISTv1.1 by real-time IRR
+5 more
Other outcome measures
Evaluate Quality of Life
ORR per RECISTv1.1 by Investigator assessment
PFS per RECISTv1.1 by Investigator assessment
+1 more

ChonDRAgon Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: INBRX-109Experimental Treatment1 Intervention
IV every three weeks
Group II: PlaceboPlacebo Group1 Intervention
IV every three weeks

Find a Location

Who is running the clinical trial?

Inhibrx, Inc.Lead Sponsor
8 Previous Clinical Trials
1,546 Total Patients Enrolled
1 Trials studying Chondrosarcoma
240 Patients Enrolled for Chondrosarcoma
Klaus Wagner, MD PhDStudy DirectorInhibrx, Inc.
1 Previous Clinical Trials
31 Total Patients Enrolled
Vasily Andrianov, MDStudy DirectorInhibrx, Inc.
4 Previous Clinical Trials
904 Total Patients Enrolled
1 Trials studying Chondrosarcoma
240 Patients Enrolled for Chondrosarcoma

Media Library

INBRX-109 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04950075 — Phase 2
Chondrosarcoma Research Study Groups: INBRX-109, Placebo
Chondrosarcoma Clinical Trial 2023: INBRX-109 Highlights & Side Effects. Trial Name: NCT04950075 — Phase 2
INBRX-109 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04950075 — Phase 2
Chondrosarcoma Patient Testimony for trial: Trial Name: NCT04950075 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there many locations conducting this research in Canada?

"OHSU Knight Cancer Institute, Columbia University and Thomas Jefferson University Hospital are the prime sites for this trial with an additional 30 clinical centres in operation. The three primary locations are situated in Portland, Oregon; New york City, NY; and Philadelphia, Pennsylvania respectively."

Answered by AI

Could you elaborate on the potential risks of using INBRX-109?

"As INBRX-109 is in Phase 2, our team at Power estimated its safety to be a score of 2 due to existing evidence for safety but not yet efficacy."

Answered by AI

How many individuals are partaking in this medical experiment?

"For this investigation to be successful, 201 participants that adhere to the set inclusion criteria must partake in it. OHSU Knight Cancer Institute and Columbia University are two of several sites offering enrolment into this study."

Answered by AI

Is this research program currently recruiting participants?

"Verified. Clinicaltrials.gov provides evidence that recruitment for this trial is currently active, and began on September 23rd 2021. The most recent update was logged on November 23rd 2022 and the study aims to include 201 individuals across 30 sites."

Answered by AI

Who else is applying?

What state do they live in?
Oklahoma
Washington
Arizona
What site did they apply to?
Oklahoma State University (OSU) - Stephenson Cancer Center
Mayo Clinic - Arizona
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Right kidney removed tumor cause failure drugged at hospital will never go back.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Study of INBRX-109 in Conventional Chondrosarcoma
2021. "Study of INBRX-109 in Conventional Chondrosarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04950075.
All > Chondrosarcoma
~56 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top